Mylatabi (Eltrombopag)

Eltrombopag acts on the thrombopoietin pathway to increase platelet production in several hematologic disorders.

• Chronic immune thrombocytopenia (ITP): raises platelet counts in patients with persistent low platelet levels.
• Aplastic anemia: stimulates residual marrow to produce more platelets, improving thrombocytopenia.
• Severe thrombocytopenia associated with chronic hepatitis C: helps achieve safer platelet levels during antiviral therapy.

• Eltrombopag is a small‑molecule agonist of the thrombopoietin (TPO) receptor c‑Mpl on megakaryocyte progenitor cells. Binding activates intracellular signaling that promotes proliferation and differentiation of these precursors, resulting in increased platelet production and elevated circulating platelet counts.

Eltrombopag may cause a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea: occasional, often transient.
• Diarrhea: may be watery or loose.
• Fatigue: general feeling of tiredness.
• Elevated liver enzymes: mild transaminase increases.
• Dyspepsia: indigestion or stomach discomfort.

Serious or Rare Side Effects

• Thromboembolic events: clot formation in veins or arteries.
• Severe liver injury: marked elevation of hepatic enzymes or hepatitis.
• Cataract formation: lens opacity reported with long‑term use.
• Severe neutropenia: marked reduction in neutrophil count.
• Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Before initiating therapy, several safety considerations should be addressed.

• Monitor platelet counts: adjust therapy based on response and target levels.
• Assess liver function: obtain baseline and periodic transaminases.
• Screen for thrombotic risk: avoid in patients with active or uncontrolled thrombosis.
• Use in pregnancy only if benefits outweigh risks: limited data available.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Eltrombopag can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: markedly reduce oral absorption of eltrombopag.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations and diminish effect.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): can increase eltrombopag levels.

• Concurrent use with other myelosuppressive agents: requires close monitoring of blood counts.
• Herbal supplements such as St. John's wort: may alter metabolism and affect drug exposure.